Group 1 - InxMed Limited-B (应世生物) submitted its Hong Kong IPO prospectus on August 25, 2025, which will expire on February 25, 2026, with CITIC Securities and Jianyin International as joint sponsors [1] - InxMed is a late-stage biotechnology company founded in 2017, focused on improving current cancer treatment options that have limited efficacy [2] - The company's mission is to address the core challenges of cancer treatment, specifically resistance caused by tumor defenses [2] Group 2 - InxMed targets key signaling hubs common across various tumor types, particularly the FAK and integrin pathways, which play a critical role in tumor cell survival and contribute to treatment failures [2] - The company aims to dismantle the protective barriers surrounding tumor cells by targeting cancer-associated fibroblasts (CAFs) [2] - By focusing on key pathways related to drug resistance, InxMed seeks to reshape rational drug use in cancer treatment and open new frontiers for therapeutic innovation [2]
应世生物港股IPO招股书失效
Zhi Tong Cai Jing·2026-02-24 23:03